GlaxoSmithKline's poaching of pharma industry veteran Luke Miels from AstraZeneca in January was billed as an early win success for incoming CEO Emma Walmsley, who scrambled to replace global pharma president Abbas Hussain and other departing execs.
Fast-forward to the present, and the appointment has opened a can of worms. Bloomberg reported that Miels is currently on "gardening leave" from AZ after facing a lawsuit from his current employer alleging breach of employment.
AZ wants Miels to honor the terms of the contract he signed as executive VP of its European pharma business and has taken to the courts to try to force him to do so, according to the newswire.
No comments:
Post a Comment